Cardiac Valve Centre, Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University-Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.
Cardiac Valve Centre, Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University-Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.
Heart Lung Circ. 2020 Jun;29(6):940-948. doi: 10.1016/j.hlc.2019.05.189. Epub 2019 Jul 2.
We aimed to evaluate the therapeutic effectiveness of commissuroplasty in mitral valve repair for rheumatic mitral valve disease. For this purpose, we summarise our experience with this technique and analyse the mid-term postoperative outcomes.
We retrospectively evaluated the records of patients with rheumatic valve disease who underwent mitral valve repair between January 2011 and January 2018 at our centre. Detailed follow-up data were collected. A Kaplan-Meier survival curve for survival free from reoperation and valve failure was constructed. Multivariate Cox regression analyses were performed to identify predictors of relevant end points (death, reoperation, and valve failure).
A total of 362 patients underwent rheumatic mitral valve repair during the study period. Mitral valve stenosis was the primary pathological feature. Almost all surgeries were accomplished via commissuroplasty. The mean duration of follow-up was 25.57 ± 19.91 months. Twenty-two (22) endpoint events were noted during follow-up. The 2- and 7-year rates of survival free from reoperation and valve failure were 93.9%±1.4% and 91.5%±2.0%, respectively. Multivariate Cox regression analysis revealed that left atrial anteroposterior diameter >60 mm (hazard ratio, 5.2; p < 0.001) was an independent predictor of all endpoints.
Most Chinese patients with rheumatic valve disease were treated effectively via commissuroplasty combined with other surgical procedures, and the mid-term postoperative outcomes were satisfactory.
评估二尖瓣修复术中行交界切开术治疗风湿性二尖瓣疾病的疗效。为此,我们总结了该技术的经验,并分析了中期术后结果。
我们回顾性评估了 2011 年 1 月至 2018 年 1 月期间在我们中心接受二尖瓣修复术的风湿性瓣膜病患者的病历。收集了详细的随访数据。构建了免于再次手术和瓣膜失效的生存Kaplan-Meier 生存曲线。进行多变量 Cox 回归分析以确定相关终点(死亡、再次手术和瓣膜失效)的预测因素。
研究期间共有 362 例患者接受了风湿性二尖瓣修复术。二尖瓣狭窄是主要的病理特征。几乎所有手术均通过交界切开术完成。平均随访时间为 25.57±19.91 个月。随访期间共发生 22 例终点事件。免于再次手术和瓣膜失效的 2 年和 7 年生存率分别为 93.9%±1.4%和 91.5%±2.0%。多变量 Cox 回归分析显示,左心房前后径>60mm(危险比,5.2;p<0.001)是所有终点的独立预测因素。
大多数中国风湿性瓣膜病患者通过交界切开术联合其他手术治疗取得了良好的疗效,中期术后结果令人满意。